Health

  • October 23, 2026

    Crowell & Moring Hires 10-Year DOJ Healthcare Litigator

    Crowell & Moring LLP has hired a U.S. Department of Justice litigator who has spent the past decade as a senior trial lawyer in the Civil Division's commercial litigation branch, the firm recently announced.

  • October 23, 2026

    Insurer Can't Exit Captive Carrier Fight, NC Justices Rule

    The North Carolina Supreme Court on Friday backed a state Business Court decision denying a Georgia insurance company's bid to dismiss third-party claims brought against it in a shareholder dispute over the demise of a defunct captive insurer.

  • October 23, 2026

    Hims & Hers Says Privacy Policy, Disclosures Foil FTC Suit

    Hims & Hers Health Inc. urged a California federal court to dismiss the Federal Trade Commission's suit accusing it of misleading consumers about its privacy and billing practices, arguing the agency ignored the telehealth platform's disclosures about those practices in an attempt to "manufacture deception."

  • October 23, 2026

    Nurse Says NY Health System Forced Pregnancy Leave

    New York's largest health system required a pregnant nurse to take leave rather than accommodate her when she asked to take breaks and not lift more than 10 pounds throughout her high-risk pregnancy, according to a new suit filed in federal court.

  • October 22, 2026

    DOJ Tackles Largest-Ever Sham Drug Treatment, Other Frauds

    The U.S. Department of Justice on Thursday announced criminal charges against 15 people in several alleged healthcare fraud schemes in the Los Angeles area, including what prosecutors called the largest substance abuse treatment fraud ever prosecuted by the federal government.

  • October 22, 2026

    DEA Judge Will Not Reopen Marijuana Rescheduling Hearing

    The coalition fighting marijuana legalization won a partial victory after a Drug Enforcement Administration's administrative law judge on Thursday allowed into the record a U.S. Government Accountability Office report the group championed but denied new testimony on it, saying the report "speaks for itself."

  • October 22, 2026

    Zimmer Biomet Can't Slip Sales Rep Kickback Claims

    A Massachusetts federal judge has ruled that Zimmer Biomet can't avoid a whistleblower's claims that commissions it paid to independent contractors to sell orthopedic products to surgeons were unlawful kickbacks.

  • October 22, 2026

    Gilead Reaches $45M Settlement To End Kickback Claims

    The Texas Office of the Attorney General on Thursday announced that pharmaceutical company Gilead Sciences Inc. signed off on a $45 million settlement to end claims that the company ran an illegal kickback scheme in order to get prescribers to favor its medications.

  • October 22, 2026

    Full 9th Circ. Won't Review Surgical Robot Antitrust Fight

    The full Ninth Circuit declined to reconsider an appellate panel's recent decision reviving a surgical repair company's antitrust suit alleging Intuitive Surgical blocked third parties from supplying parts for its popular da Vinci surgery robot, according to an order issued Thursday.

  • October 22, 2026

    J&J Says Justices' Denial Backs Tossing Fee Suit At 3rd Circ.

    Johnson & Johnson told the Third Circuit Thursday that the U.S. Supreme Court's recent decision not to take up a group of executives' federal benefits dispute backed its position in an appeal from J&J workers who alleged their health plans were saddled with excessive prescription drug fees.

  • October 22, 2026

    Mylan Settles Connecticut's EpiPen Price Claims For $8M

    Mylan Pharmaceuticals has struck another deal to resolve claims that it illegally inflated prices for EpiPens, this time settling Connecticut state enforcers' allegations of antitrust and consumer protection law violations for $8 million.

  • October 22, 2026

    NJ Panel Lets Nursing Home Arbitrate Resident Death Suit

    A New Jersey state appeals court on Thursday declined to disturb an order forcing a widow to arbitrate medical negligence and wrongful death claims against a nursing home, agreeing it didn't waive its right to arbitration by participating in litigation for over a year.

  • October 22, 2026

    Judge Says BCBS' Evidence Ask In Ford Case Too Late

    A Michigan federal judge on Thursday denied Blue Cross Blue Shield of Michigan's motion to compel Ford Motor Company to produce emails from a senior director, ruling that the health insurer waited too long to make the request in the antitrust suit.

  • October 22, 2026

    Hospital Tells DC Circ. Talks Tainted Nurses Union Election

    A hospital urged the D.C. Circuit to reverse a National Labor Relations Board decision affirming its obligation to bargain with the Oregon Nurses Association, saying the board misapplied precedent when it excused the union's campaigning immediately before a representation election.

  • October 22, 2026

    CMS Hit With Another Broker Suit Over ACA Registration Bar

    The Centers for Medicare & Medicaid Services has been hit with another suit by health insurance brokers alleging the agency is unlawfully blocking them from registering to help individuals find Affordable Care Act marketplace coverage for plan year 2027.

  • October 22, 2026

    'Substantially Impaired' Main Topic Of Medicaid Rule Hearing

    A Massachusetts federal judge pressed the Trump administration Thursday on its argument that Congress intentionally left it with the task of defining who is considered too medically frail to comply with Medicaid work requirements set to take effect in January.

  • October 21, 2026

    7 Firms Advise EQT, Qiagen On $12.1B Take-Private Deal

    A long list of firms — including Davis Polk & Wardwell LLP, Linklaters LLP and Milbank LLP — are steering Sweden-based EQT Private Equity's $12.1 billion takeover of life sciences testing company Qiagen NV, according to a Wednesday announcement.

  • October 21, 2026

    Reckitt Benckiser Denies Firing Manager For Whistleblowing

    Reckitt Benckiser urged a New Jersey federal judge to end a former senior regulatory manager's suit alleging she was fired for raising product safety issues, arguing Tuesday she rejected a lateral transfer amid a global reorganization and unsuccessfully gambled the company would give in to her promotion and higher pay demands.

  • October 21, 2026

    Ill. Judge Questions Bid To Block 340B Drug Discount Law

    An Illinois federal judge seemed hesitant Wednesday to halt a state law barring drugmakers from trying to impose restrictions on pharmacies under contract with a federal drug pricing discount program, saying the state seems to be maximizing public health in an area the statute doesn't address.

  • October 21, 2026

    9th Circ. Judges Hint Hospital CBA May Mandate Arbitration

    A Ninth Circuit panel appeared receptive on Wednesday to Long Beach Memorial Medical Center's argument that a nurse should be forced to individually arbitrate proposed class break claims, with two judges suggesting that a union contract's repeated references to Golden State labor law bolster the hospital's position.

  • October 21, 2026

    PBM Fee Disclosure Rule Clears White House Review

    A White House budget office has completed review of a rule from the U.S. Department of Labor's employee benefits arm that would require new fee disclosures from pharmacy benefit managers, which act as intermediaries between drugmakers, pharmacies and insurers.

  • October 21, 2026

    4 Firms Steer Cencora's $2.4B American Oncology Acquisition

    Pharmaceutical distribution company Cencora unveiled plans Wednesday to acquire American Oncology Network Inc. in a deal that values the network at an enterprise value of $2.4 billion and was built by four law firms.

  • October 21, 2026

    Linde Seeks $1.2M Clawback From Exec Who Joined Rival

    International industrial and healthcare gas supplier Linde PLC is seeking to recover more than $1.2 million in stock and performance rewards gains from Joseph H. Porto III, the onetime executive director of growth at Linde Gases U.S., after Porto allegedly left for a competitor.

  • October 21, 2026

    Intuitive Surgical Strikes $450M Deal In Robot Antitrust Suit

    Intuitive Surgical said in its quarterly earnings report Tuesday that it reached a $450 million settlement to resolve a hospital class action alleging it monopolized the market for servicing its da Vinci surgical robots, subject to approval by a California federal judge.

  • October 21, 2026

    Amarin Ends 'Skinny Label' Patent Case Against Hikma

    Amarin Pharma Inc. is dropping its patent suit over Hikma Pharmaceuticals USA Inc.'s generic version of a heart drug that uses a so-called skinny label, months after the U.S. Supreme Court shut the case down.

Expert Analysis

  • DOJ Policy Creates New Defense For Physicians, Health Cos.

    Author Photo

    The U.S. Department of Justice's recently revised enforcement policy governing agency guidance makes clear that Medicare guidance is not the law, potentially giving healthcare organizations a stronger basis to challenge certain enforcement theories, says Jose Vela at Clark Hill.

  • $95M Nev. Case Provides Clues On Wound Care Enforcement

    Author Photo

    Federal prosecutors’ recent U.S. v. Dubin indictment, charging a Nevada physician with healthcare fraud over an alleged $95 million Medicare billing scheme involving amniotic wound allografts, provides a clearer picture of an increasingly data-driven enforcement strategy that follows the entire wound care transaction, say attorneys at Bass Berry.

  • 8th Circ. Ruling Raises Bar For Seeking Disability Benefits

    Author Photo

    The Eighth Circuit's recent ruling in Post v. Bisignano signals that claimants seeking Social Security disability benefits may need to offer convincing proof of functional restrictions beyond their treating doctors' opinions and illustrates that the court's proclaimant jurisprudence no longer prevails, says Mark DeBofsky at DeBofsky Law.

  • FCA Ruling May Open Door To Redacting Defendants' Names

    Author Photo

    A recent Florida federal court decision may signal a shift from the long-prevailing view that False Claims Act defendants' identities must always be revealed when qui tam actions are unsealed, potentially providing important protection for healthcare fraud defendants who may face career consequences from unproven allegations, say attorneys at Holland & Knight.

  • 4 Tips On Expert Gatekeeping From J&J Talc Deal

    Author Photo

    Johnson & Johnson's successful campaign to exclude plaintiff-side oncologist testimony about whether its talcum powder caused ovarian cancer, which prompted the recent resolution of 70,000 claims, offers lessons on how product liability defendants can reshape risk calculation by rigorously applying expert admissibility rules, say attorneys at Hollingsworth.

  • Series

    Playing Bid Whist Makes Me A Better Lawyer

    Author Photo

    As a child, I viewed bid whist as a family tradition and a source of friendly card game competition, but as a lawyer, I see it as a tool that has helped me cultivate skills like communication, teamwork, risk assessment and composure, says Keyonn Pope at Riley Safer.

  • Teva, Wyeth Show How Claimed Advances Shape Enablement

    Author Photo

    Two recent Federal Circuit decisions involving method-of-treatment claims — Teva v. Eli Lilly and Wyeth v. AstraZeneca — reached opposite enablement outcomes from strikingly similar procedural postures, but a closer comparison of the cases reveals a three-step framework for understanding the court's reasoning, says Kendall Gurule at Polsinelli.

  • Tracking Trends In State-Level Regulatory Enforcement

    Author Photo

    State-level enforcement now increasingly involves antitrust, artificial intelligence and data privacy issues, and the key for organizations to reducing risk is having the ability to respond across governance, public affairs, discovery and remediation in multiple states simultaneously, say consultants at FTI Consulting.

  • Opinion

    Calif. Bill Goes Too Far In Trying To Regulate Attorney AI Use

    Author Photo

    California’s first-in-the-nation act regulating how attorneys and arbitrators use generative artificial intelligence will likely soon become law, but read broadly, the provisions may dissuade lawyers from employing AI at all, thereby depriving them of key work tools, says Joshua Wurtzel at Schlam Stone.

  • AI Rise In Healthcare Demands New Cybersecurity Strategies

    Author Photo

    As artificial intelligence-related capabilities are increasingly integrated into medical devices and healthcare operations, organizations must adapt their compliance playbook to address evolving cybersecurity needs and implement lifecycle-based risk assessment approaches, say attorneys at Covington.

  • Hims & Hers Suit Spotlights Health Data-Sharing Privacy Risks

    Author Photo

    Regulators' complaint against telehealth company Hims & Hers alleging deceptive practices serves as a reminder that the privacy principles developed under consumer protection laws and predating omnibus statutes remain in force, and sensitive data governance continues to be a crucial component of compliance, say attorneys at Venable.

  • How Cannabis Rescheduling Is Reshaping Bankruptcy

    Author Photo

    As broader cannabis rescheduling awaits a recommended decision, cannabis companies continue to test the boundaries of the Bankruptcy Code, with the recent Cannabist Chapter 15 recognition order suggesting that governmental resistance may be reduced in future filings, say attorneys at Thompson Coburn.

  • Opinion

    New CMS Medical Device Pathway May Have Limited Effect

    Author Photo

    The Centers for Medicare & Medicaid Services' new pathway for giving Medicare beneficiaries earlier access to certain medical devices bears similarities to previous programs that did not advance coverage significantly, and thus may only benefit certain manufacturers, say attorneys at King & Spalding.

  • A Road Map To Modernizing Clinical Lab Regulations

    Author Photo

    The Centers for Medicare & Medicaid Services' recent request for comments on potential changes to the Clinical Laboratory Improvement Amendments provides an early indication of where CLIA is headed, and the operational, compliance, reimbursement and enforcement issues those changes will create, says Jose Vela at Clark Hill.

  • How GCs Can Assess The Risks Of Emerging AI Laws

    Author Photo

    Amid a swirl of momentous legislative activity aimed at regulating artificial intelligence, general counsel must return to first principles when determining whether new laws will apply and whether the company’s use could cause regulators to subject it to additional regulation, say attorneys at WilmerHale.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Health archive.